Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation - PubMed
3 days ago
- #acute myeloid leukemia
- #immunotherapy
- #CAR-T therapy
- CAR-T cell therapy is an investigational strategy for treating relapsed/refractory acute myeloid leukemia (AML).
- Key challenges include target antigen scarcity and the immunosuppressive tumor microenvironment (TME).
- Preclinical advances focus on target optimization (e.g., CD33, CD123) and innovative strategies like nanobody-based CARs and logic-gated systems.
- The AML TME inhibits CAR-T function, but interventions like immune checkpoint blockade and cytokine arming are being explored.
- Emerging technologies include off-the-shelf CAR-T, CAR-NK cells, and γδ T cell therapy.
- Despite promising preclinical results, there is a gap in translating these to consistent clinical success.
- Multidimensional innovation and combination therapies are critical for overcoming AML-specific barriers.